394 related articles for article (PubMed ID: 25186065)
21. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
[TBL] [Abstract][Full Text] [Related]
22. Taxane-based mono- or combination therapy for managing metastatic breast cancer (MBC) in routine practice: a multinational prospective observational study.
Gümüş M; Davidson N; Bauknecht T; Soldatenkova V; Benhadji KA
Curr Med Res Opin; 2012 Mar; 28(3):401-13. PubMed ID: 22181343
[TBL] [Abstract][Full Text] [Related]
23. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24).
Steger GG; Greil R; Lang A; Rudas M; Fitzal F; Mlineritsch B; Hartmann BL; Bartsch R; Melbinger E; Hubalek M; Stoeger H; Dubsky P; Ressler S; Petzer AL; Singer CF; Muss C; Jakesz R; Gampenrieder SP; Zielinski CC; Fesl C; Gnant M;
Ann Oncol; 2014 Feb; 25(2):366-71. PubMed ID: 24347519
[TBL] [Abstract][Full Text] [Related]
24. Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy.
Baron P; Beitsch P; Boselli D; Symanowski J; Pellicane JV; Beatty J; Richards P; Mislowsky A; Nash C; Lee LA; Murray M; de Snoo FA; Stork-Sloots L; Gittleman M; Akbari S; Whitworth P
Ann Surg Oncol; 2016 May; 23(5):1522-9. PubMed ID: 26714960
[TBL] [Abstract][Full Text] [Related]
25. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
26. Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer.
Korde LA; Lusa L; McShane L; Lebowitz PF; Lukes L; Camphausen K; Parker JS; Swain SM; Hunter K; Zujewski JA
Breast Cancer Res Treat; 2010 Feb; 119(3):685-99. PubMed ID: 20012355
[TBL] [Abstract][Full Text] [Related]
27. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
[TBL] [Abstract][Full Text] [Related]
28. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer.
Kim MM; Allen P; Gonzalez-Angulo AM; Woodward WA; Meric-Bernstam F; Buzdar AU; Hunt KK; Kuerer HM; Litton JK; Hortobagyi GN; Buchholz TA; Mittendorf EA
Ann Oncol; 2013 Aug; 24(8):1999-2004. PubMed ID: 23562929
[TBL] [Abstract][Full Text] [Related]
29. Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.
Gion M; García-Mosquera JJ; Pérez-García JM; Peg V; Ruiz-Borrego M; Stradella A; Bermejo B; Guerrero JA; López-Montero L; Mancino M; Rodríguez-Morató J; Antonarelli G; Sampayo-Cordero M; Llombart-Cussac A; Cortés J
Breast Cancer Res Treat; 2024 Jun; 205(3):589-598. PubMed ID: 38456970
[TBL] [Abstract][Full Text] [Related]
30. Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients.
Nguyen B; Cusumano PG; Deck K; Kerlin D; Garcia AA; Barone JL; Rivera E; Yao K; de Snoo FA; van den Akker J; Stork-Sloots L; Generali D
Ann Surg Oncol; 2012 Oct; 19(10):3257-63. PubMed ID: 22965266
[TBL] [Abstract][Full Text] [Related]
31. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX).
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Saarni O; Helle L; Villman K; Nyandoto P; Nilsson G; Leinonen M; Kataja V; Bono P; Lindman H
Acta Oncol; 2014 Feb; 53(2):186-94. PubMed ID: 23957715
[TBL] [Abstract][Full Text] [Related]
32. A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer.
A L-Tweigeri T; AlSayed A; Alawadi S; Ibrahim M; Ashour W; Jaafar H; Abulkhair O; A L-Abdulkarim H; Khalid H; Ajarim D;
Cancer Chemother Pharmacol; 2016 Jan; 77(1):147-53. PubMed ID: 26563257
[TBL] [Abstract][Full Text] [Related]
33. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
Michalaki V; Fotiou S; Gennatas S; Gennatas C
Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer.
Layman RM; Thomas DG; Griffith KA; Smerage JB; Helvie MA; Roubidoux MA; Diehl KM; Newman LA; Sabel MS; Hayman JA; Pierce LJ; Hayes DF; Schott AF
Clin Cancer Res; 2007 Jul; 13(14):4092-7. PubMed ID: 17634534
[TBL] [Abstract][Full Text] [Related]
35. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
[TBL] [Abstract][Full Text] [Related]
36. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.
Fernández-Cuesta L; Oakman C; Falagan-Lotsch P; Smoth KS; Quinaux E; Buyse M; Dolci MS; Azambuja ED; Hainaut P; Dell'orto P; Larsimont D; Francis PA; Crown J; Piccart-Gebhart M; Viale G; Leo AD; Olivier M
Breast Cancer Res; 2012 May; 14(3):R70. PubMed ID: 22551440
[TBL] [Abstract][Full Text] [Related]
37. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
38. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
[TBL] [Abstract][Full Text] [Related]
39. The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy.
Vici P; Mottolese M; Pizzuti L; Barba M; Sperati F; Terrenato I; Di Benedetto A; Natoli C; Gamucci T; Angelucci D; Ramieri MT; Di Lauro L; Sergi D; Bartucci M; Dattilo R; Pagliuca A; De Maria R; Maugeri-Saccà M
Oncotarget; 2014 Oct; 5(20):9619-25. PubMed ID: 25294813
[TBL] [Abstract][Full Text] [Related]
40. Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.
Kimbung S; Markholm I; Bjöhle J; Lekberg T; von Wachenfeldt A; Azavedo E; Saracco A; Hellström M; Veerla S; Paquet E; Bendahl PO; Fernö M; Bergh J; Loman N; Hatschek T; Hedenfalk I;
Int J Cancer; 2018 Feb; 142(3):618-628. PubMed ID: 28940389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
